Logistic regression for STROKE3 case fatality for new cases during follow-up, multiplicative allele effects

Rank SNP name in MORGAM RS-code Chromosome Success Genotype Cases Non-cases Total OR (95% CI) nominal p-value tail-area FDR
1 MIA3_MG_454 rs3008621 1 98.6% A/A 3 (10%) 8 (2%) 11 2.170
(1.162, 4.054)		 0.01508 0.55803
A/G 10 (33%) 91 (23%) 101
G/G 17 (57%) 290 (75%) 307
2 2Q36_3_MG_433 rs2972147 2 100.0% C/C 7 (23%) 163 (41%) 170 0.550
(0.317, 0.953)		 0.03307 0.61183
C/T 17 (55%) 186 (47%) 203
T/T 7 (23%) 45 (11%) 52
3 9P21_3_MG_425 rs1333049 9 100.0% C/C 2 (6%) 77 (20%) 79 0.603
(0.342, 1.063)		 0.08050 0.80800
C/G 16 (52%) 193 (49%) 209
G/G 13 (42%) 124 (31%) 137
4 2Q36_3_MG_461 rs2943634 2 96.2% A/A 7 (23%) 43 (11%) 50 1.614
(0.932, 2.793)		 0.08735 0.80800
A/C 14 (47%) 173 (46%) 187
C/C 9 (30%) 163 (43%) 172
5 9P21_3_MG_420 rs10738610 9 99.3% A/A 13 (42%) 121 (31%) 134 1.565
(0.895, 2.738)		 0.11643 0.86156
A/C 15 (48%) 193 (49%) 208
C/C 3 (10%) 77 (20%) 80
6 SMAD3_MG_452 rs17228212 15 99.1% C/C 0 (0%) 22 (6%) 22 0.598
(0.282, 1.265)		 0.17845 0.94850
C/T 9 (30%) 140 (36%) 149
T/T 21 (70%) 229 (59%) 250
7 SMAD3_MG_431 rs1866317 15 100.0% C/C 2 (6%) 7 (2%) 9 1.549
(0.773, 3.104)		 0.21682 0.94850
C/G 8 (26%) 100 (25%) 108
G/G 21 (68%) 287 (73%) 308
8 FMN2_MG_450 rs1456648 1 98.8% G/G 0 (0%) 13 (3%) 13 0.637
(0.269, 1.512)		 0.30697 0.94850
G/T 6 (20%) 85 (22%) 91
T/T 24 (80%) 292 (75%) 316
9 SEZ6L_MG_427 rs137209 22 100.0% A/A 4 (13%) 41 (10%) 45 1.309
(0.766, 2.239)		 0.32512 0.94850
A/G 15 (48%) 155 (39%) 170
G/G 12 (39%) 198 (50%) 210
10 1Q31_2_MG_453 rs1936982 1 99.1% C/C 6 (20%) 43 (11%) 49 1.331
(0.749, 2.363)		 0.32963 0.94850
C/T 12 (40%) 181 (46%) 193
T/T 12 (40%) 167 (43%) 179
11 MIA3_MG_430 rs17465637 1 99.8% A/A 7 (23%) 29 (7%) 36 1.310
(0.756, 2.270)		 0.33579 0.94850
A/C 6 (19%) 143 (36%) 149
C/C 18 (58%) 221 (56%) 239
12 SEZ6L_MG_426 rs137205 22 100.0% A/A 3 (10%) 35 (9%) 38 1.255
(0.728, 2.164)		 0.41383 0.94850
A/G 15 (48%) 146 (37%) 161
G/G 13 (42%) 213 (54%) 226
13 5Q21_1_MG_435 rs436495 5 99.1% A/A 3 (10%) 27 (7%) 30 1.240
(0.701, 2.192)		 0.46018 0.94850
A/G 11 (35%) 128 (33%) 139
G/G 17 (55%) 235 (60%) 252
14 SEZ6L_MG_444 rs688034 22 99.8% C/C 15 (48%) 223 (57%) 238 0.807
(0.454, 1.435)		 0.46479 0.94850
C/T 13 (42%) 146 (37%) 159
T/T 3 (10%) 24 (6%) 27
15 SEZ6L_MG_442 rs6005015 22 100.0% C/C 3 (10%) 36 (9%) 39 1.173
(0.671, 2.051)		 0.57585 0.94850
C/T 15 (48%) 162 (41%) 177
T/T 13 (42%) 196 (50%) 209
16 10Q11_21_MG_428 rs1746048 10 100.0% C/C 23 (74%) 281 (71%) 304 1.238
(0.558, 2.745)		 0.59918 0.94850
C/T 8 (26%) 104 (26%) 112
T/T 0 (0%) 9 (2%) 9
17 10Q11_21_MG_443 rs687175 10 100.0% C/C 0 (0%) 9 (2%) 9 0.808
(0.364, 1.791)		 0.59918 0.94850
C/T 8 (26%) 104 (26%) 112
T/T 23 (74%) 281 (71%) 304
18 10Q11_21_MG_458 rs622472 10 98.6% A/A 22 (73%) 278 (71%) 300 1.191
(0.534, 2.654)		 0.66890 0.94850
A/C 8 (27%) 102 (26%) 110
C/C 0 (0%) 9 (2%) 9
19 10Q11_21_MG_429 rs1746049 10 100.0% C/C 24 (77%) 299 (76%) 323 1.199
(0.515, 2.788)		 0.67377 0.94850
C/T 7 (23%) 89 (23%) 96
T/T 0 (0%) 6 (2%) 6
20 10Q11_21_MG_456 rs513391 10 99.1% A/A 22 (73%) 280 (72%) 302 1.185
(0.532, 2.641)		 0.67770 0.94850
A/C 8 (27%) 102 (26%) 110
C/C 0 (0%) 9 (2%) 9
21 9P21_3_MG_451 rs1537378 9 99.1% A/A 4 (13%) 50 (13%) 54 1.117
(0.646, 1.931)		 0.69188 0.94850
A/G 16 (53%) 192 (49%) 208
G/G 10 (33%) 149 (38%) 159
22 10Q11_21_MG_440 rs559580 10 99.8% C/C 0 (0%) 9 (2%) 9 0.852
(0.384, 1.890)		 0.69276 0.94850
C/T 8 (27%) 103 (26%) 111
T/T 22 (73%) 282 (72%) 304
23 5Q21_1_MG_455 rs383830 5 99.1% A/A 2 (7%) 21 (5%) 23 1.123
(0.608, 2.076)		 0.71117 0.94850
A/T 10 (33%) 125 (32%) 135
T/T 18 (60%) 245 (63%) 263
24 5Q21_1_MG_436 rs449650 5 99.5% G/G 18 (60%) 246 (63%) 264 0.899
(0.487, 1.658)		 0.73241 0.94850
G/T 10 (33%) 126 (32%) 136
T/T 2 (7%) 21 (5%) 23
25 PSRC1_MG_460 rs599839 1 99.1% A/A 18 (58%) 224 (57%) 242 0.904
(0.482, 1.695)		 0.75338 0.94850
A/G 11 (35%) 148 (38%) 159
G/G 2 (6%) 18 (5%) 20
26 19Q12_MG_422 rs11670734 19 100.0% C/C 2 (6%) 36 (9%) 38 1.091
(0.609, 1.957)		 0.76945 0.94850
C/G 15 (48%) 158 (40%) 173
G/G 14 (45%) 200 (51%) 214
27 2Q36_3_MG_447 rs7597168 2 100.0% C/C 17 (55%) 224 (57%) 241 1.082
(0.570, 2.055)		 0.80946 0.94850
C/T 13 (42%) 146 (37%) 159
T/T 1 (3%) 24 (6%) 25
28 5Q21_1_MG_441 rs565928 5 100.0% C/C 19 (61%) 247 (63%) 266 0.931
(0.506, 1.712)		 0.81766 0.94850
C/T 10 (32%) 126 (32%) 136
T/T 2 (6%) 21 (5%) 23
29 9P21_3_MG_459 rs7865618 9 99.1% A/A 9 (30%) 127 (32%) 136 0.942
(0.548, 1.617)		 0.82712 0.94850
A/G 16 (53%) 200 (51%) 216
G/G 5 (17%) 64 (16%) 69
30 19Q12_MG_446 rs7250581 19 98.6% A/A 0 (0%) 11 (3%) 11 0.921
(0.416, 2.036)		 0.83831 0.94850
A/G 8 (26%) 94 (24%) 102
G/G 23 (74%) 283 (73%) 306
31 9P21_3_MG_437 rs496892 9 99.8% C/C 7 (23%) 96 (24%) 103 1.054
(0.613, 1.813)		 0.84792 0.94850
C/T 19 (61%) 208 (53%) 227
T/T 5 (16%) 89 (23%) 94
32 MTHFD1L_MG_445 rs6922269 6 100.0% A/A 2 (6%) 26 (7%) 28 0.950
(0.511, 1.765)		 0.87052 0.94850
A/G 9 (29%) 126 (32%) 135
G/G 20 (65%) 242 (61%) 262
33 10Q11_21_MG_439 rs501120 10 96.9% C/C 0 (0%) 9 (2%) 9 0.943
(0.429, 2.072)		 0.88418 0.94850
C/T 8 (26%) 91 (24%) 99
T/T 23 (74%) 281 (74%) 304
34 CELSR2_MG_438 rs4970834 1 100.0% C/C 20 (65%) 248 (63%) 268 0.957
(0.506, 1.808)		 0.89209 0.94850
C/T 9 (29%) 129 (33%) 138
T/T 2 (6%) 17 (4%) 19
35 9P21_3_MG_421 rs10757283 9 99.8% C/C 5 (16%) 103 (26%) 108 1.032
(0.596, 1.787)		 0.90990 0.94850
C/T 21 (68%) 196 (50%) 217
T/T 5 (16%) 94 (24%) 99
36 SMAD3_MG_424 rs12913547 15 100.0% C/C 1 (3%) 23 (6%) 24 0.970
(0.519, 1.813)		 0.92287 0.94850
C/T 15 (48%) 168 (43%) 183
T/T 15 (48%) 203 (52%) 218
37 12Q12_MG_448 rs7970834 12 100.0% G/G 7 (23%) 120 (30%) 127 0.992
(0.574, 1.715)		 0.97803 0.97803
G/T 20 (65%) 195 (49%) 215
T/T 4 (13%) 79 (20%) 83

adjusted for: cohort strage3 sex

Updated on 2008-12-08